SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
783Kosan Prices Registered Direct Offering Friday February 9, 9:12 am ET HAYWARD, Icebrg-2/9/2007
782[Hsp-90 Inhibitors as . . . antivirals?] >>Genes Dev. 2007 Jan 1tuck-2/9/2007
781Phase I Study of the Novel Epothilone Analog Ixabepilone (BMS-247550) in PatientIcebrg-2/1/2007
780>>I have serious doubts about the value of having Pfizer as a development nigel bates-1/23/2007
779Maybe they will get it back, so they can sell it a second time. After the NBIXIcebrg-1/23/2007
778And now a month later pfizer says it's exiting gastroenterology. Wonder wherrkrw-1/23/2007
777Inhibition of heat shock protein-90 modulates multiple functions required for suIcebrg-1/20/2007
776[17-AAG, prevents the ligand-independent nuclear localization of androgen recepttuck-1/16/2007
775Somebody still seems to be still buying. I don't remember management "Steve Lokness-1/8/2007
774[Conforma: Dimeric ansamycins-A new class of antitumor Hsp90 modulators with protuck-1/7/2007
773well..given the firing of the CEO (man he was feeding fat off the option trough)mopgcw-1/6/2007
772I'd like to think the incoherence in that piece was due to the AP writer, antuck-1/6/2007
771Kosan Rises on New "Outperform" Rating Friday January 5, 12:47 pm ET mopgcw-1/6/2007
770[Total synthesis and biological evaluation of a C(10)/C(12)-phenylene-bridged antuck-12/30/2006
769[Alleviating Neurodegeneration by an Anticancer Agent: An Hsp90 Inhibitor (17-AAtuck-12/24/2006
768Kosan, Pfizer In $250M Deal For Motilin Agonist Program By Karen Pihl-Carey SeniIcebrg-12/22/2006
767Yes, no doubt it was a good deal. But inconsequential for the company's prosIcebrg-12/21/2006
766But a very good deal for a preclin program. kosn did the best they could since trkrw-12/21/2006
765Kosan's market cap increased by about 18 mUSD yesterday after the company anIcebrg-12/21/2006
764Kosan Announces License of Motilin Agonist Program to Pfizer Wednesday December Icebrg-12/20/2006
763[Clinical modulation of glutathione may enhance the efficacy of Hsp90-directed ttuck-12/16/2006
762Kosan's Hsp90 Inhibitor, Tanespimycin, Shows Promising Antitumor Activity inIcebrg-12/14/2006
761[17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma]tuck-12/13/2006
760Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows Antitumor Activity in MultIcebrg-12/11/2006
759Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows Antitumor ActIcebrg-12/11/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News